HUTCHMED (China) Limited

HCM

KYG4672N1198

Pharmaceuticals

Delayed London S.E. Other stock markets 06:35:04 2024-04-26 am EDT			5-day change	1st Jan Change
304 ^GBX	0.00%		+12.59%	+7.42%

Apr. 05	Hutchmed to Present New Data at US Cancer Research Conference	MT
Apr. 05	HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024	CI

HUTCHMED Limited Provides Revenue Guidance for the Year 2021

July 28, 2021 at 07:00 am EDT

HUTCHMED (China) Limited provided revenue guidance for the year 2021. For the year, the company expects Oncology/Immunology consolidated revenues of $110 – $130 million.

Latest news about HUTCHMED (China) Limited

Hutchmed to Present New Data at US Cancer Research Conference	Apr. 05	MT
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024	Apr. 05	CI
Hutchmed endometrial cancer treatment application accepted for review	Apr. 02	AN
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	Apr. 02	MT
HSBC in special payout on Canada sale; Astra FDA win	Apr. 02	AN
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	Apr. 02	CI
Sector Update: Health Care Stocks Advance Premarket Thursday	Mar. 28	MT
Hutchmed lung cancer treatment accepted for review in China	Mar. 28	AN
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China	Mar. 28	MT
JD Sports backs outlook; Spirent accepts new offer	Mar. 28	AN
Hutchmed (China)'s NDA Application Accepted by Chinese Authorities	Mar. 28	MT
HUTCHMED Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	Mar. 27	CI
Hutchmed begins registration stage for sovleplenib phase 2/3 trial	Mar. 22	AN
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug	Mar. 22	MT
Hutchmed (China) Initiates Phase II/III Clinical Trials for Autoimmune Disease Drug	Mar. 22	MT
Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	Mar. 21	CI
Hutchmed Returns to Profit in 2023; EPS Tops Estimate	Feb. 29	MT
EARNINGS: Hutchmed revenue surges, Craven House's loss widens	Feb. 28	AN
Hutchmed Swings to 2023 Profit as Revenue Increases	Feb. 28	MT
Hutchmed (China) Swings to Profit in FY23; Revenue Soars	Feb. 28	MT
Transcript : HUTCHMED Limited, 2023 Earnings Call, Feb 28, 2024	Feb. 28
HUTCHMED Limited Provides Revenue Guidance for the Year 2024	Feb. 28	CI
HUTCHMED Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Hutchmed hails fruquintinib trial results for gastric cancer treatment	Feb. 07	AN
Hutchmed Presents Phase 3 Trial Results for Gastric Cancer Drug at US Oncology Meet; Shares Rise 4%	Feb. 07	MT

Chart HUTCHMED (China) Limited

Duration

Period

More charts

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Sector

Pharmaceuticals

Calendar

2024-05-10 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for HUTCHMED (China) Limited

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.798 USD

Average target price

5.412 USD

Spread / Average Target

+42.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUTCHMED (CHINA) LIMITED	+7.42%	3.24B
NOVO NORDISK A/S	+25.80%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
ASTRAZENECA PLC	+13.15%	233B
NOVARTIS AG	+5.38%	201B
ROCHE HOLDING AG	-9.90%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B

Other Pharmaceuticals

HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Pharmaceuticals

HUTCHMED Limited Provides Revenue Guidance for the Year 2021

Latest news about HUTCHMED (China) Limited

Chart HUTCHMED (China) Limited

Company Profile

Income Statement Evolution

Ratings for HUTCHMED (China) Limited

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals